Navigation Links
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Date:8/24/2009

of age and older.

Do not take XYZAL(R) if you are allergic to XYZAL(R), cetirizine or ZYRTEC(R). Be sure to tell your doctor if you have kidney disease. Children 6 months to 11 years of age with impaired kidney function should not take XYZAL(R). Patients taking XYZAL(R) should avoid operating machinery or driving a motor vehicle.

In patients 12 years of age and older, side effects may include sleepiness, tiredness, sore throat and dry mouth. In children 6-12 years of age, side effects may include fever, cough, sleepiness and nose bleeds. In children 1-5 years of age, side effects may include fever, diarrhea, vomiting, and ear infections. In children 6 months to 11 months of age, side effects may include diarrhea and constipation.

For full prescribing information please go to www.XYZAL.com.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10,000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB). U.S. headquarters is located in Atlanta, Ga.

Forward-looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of managem'/>"/>

SOURCE UCB; sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
2. First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Programs Viability
3. Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain
4. FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
5. FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
6. FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
7. House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services
8. FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
9. FDA Approves Sculptra(R)Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
10. Kaiser Permanente Approves $11 Million in Community Benefit Grants
11. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...RONTOandCALGARY,Nov.25/PRNewswire/-SentinelleMedic...ing(MRI)coilsandsoftwareandCalgaryScientificInc.,a...introducedawebversionofAegis(TM)Breast4DAdvancedVi...isthefirsttrulyzero-footprintWebclientbasedmedical...Web(TM)platformallowsforzero-footprintaccess-requi...
(Date:11/25/2009)...LVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anar...forDrugEvaluationandResearch,titled"ADifficultBala...theNov.26,2009issueofTheNewEnglandJournalofMedicin...h/20090824/FDALOGO ) ,, Inthearticle,Woodcockdi...inmedicationforthosewhoneeditandmanagingtheriskspo...
(Date:11/25/2009)...roadPoliticalEndorsements,Business,andPressJoinEff...e-USNewswire/--Onceagain,theNationalBipolarFoundat...ndorsingtheir"Safe,tilStable"program,whichisnowbei...ipolardisorder.Today,theNationalBipolarFoundationr...PriorityMailfromtheLt.GovernorofLouisianaMitchLand...
(Date:11/25/2009)...uitous discovery that grew out of a collaboration ...ially offer hope to the nearly 10 million American... , Also known as hardening of the arteries, peri...latory problem in which narrowed arteries reduce b...d a red flag for vascular disease, heart attack an...
(Date:11/25/2009)... already used to fight rheumatoid arthritis, could... , WEDNESDAY, Nov. 25 (HealthDay News) -- A ... and rheumatoid arthritis now also shows some prom...1 diabetes. , The drug, rituximab (Rituxan), he...ulin, even though the disease had destroyed some o...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...acid supplements may slow cognitive decline in som... do not appear// to affect those with more advance... Alzheimer’s disease is a severely debilitati... according to background information in the articl...
... the ruling by Maryland's highest court a group of... state's medical// assistance program by Republica...The Court of Appeals voted unanimously that Ehrlic...ldren and pregnant women who were recent but legal...
...strict the use animals for the purpose of drug tes... are being developed by researchers at the Univers...130,000? as a financial grant. Gauging the ca...ety. Gentronix , a research company founded by ...
... a decline in the incidence of stroke in Perth, We...ding to new research// announced today by The Geor...l Scientific Meeting of the Stroke Society of Aust...tionally, over 53,000 strokes occur each year, of ...
...are provided by doctors and dentists according to ... which runs Barrowa€?s Furness General Hospital is...re Commission has roundly criticised the NHS servi...erformance of NHS in relation to government target...
...ut down the neo-natal intensive care unit of the R...immediate //effect was passed by the Philippine He...ts of the death of seven new born babies. Th...-natal sepsis”. . An inspection control commi...
Other Medicine News:Health News:Omega-3 May Slow Cognitive Decline in Some with Very Mild Alzheimer’ 2Health News:Health Care Benefits for Immigrants Favored by MD Court 2Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Declining Incidence of stroke in Australia 2
(Date:11/25/2009)...wire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),ac...ering,developingandcommercializingnoveldrugstotrea...calyearendedSeptember30,2009.AtSeptember30,2009Pha...ortterminvestments. ,, PipelineUpdateand2009Hi..., InlateNovember2009,anindependentDataMonitoring...
(Date:11/25/2009)...--BioTrendsResearchGroup,Inc.releasedWave1ofits L...ti-phasesyndicatedmarketresearchprojecttrackingthe...launchthroughthefirstsixmonthsofavailability.Eachw...5uniqueDermatologistsandqualitativeinformationfrom...bstaclestouse,typicalpatienttypes,productperceptio...
(Date:11/25/2009)...swire-USNewswire/--RemediumTechnologiesInc.,acompa...leeding,wonfirstprizeand$10,000intheMostPromisingS...9,companyofficialsannouncetoday. ,, Selectedfro...ampitchedtheirinventionattheGSCSecuritySummitconfe...um( www.remediumtechnologies.com )isdevelopingahig...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 1BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 2BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 3Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 1Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 2Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 1Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 2
... NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone ...ers Squibb Company (NYSE:,BMY) announced today tha...ximab) combined with platinum-based chemotherapy,m...ival in patients,with recurrent and/or metastatic ...N). The randomized, multi-center study, known as,E...
... COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-Fi...yeth , provides comment on a,re- analysis of poole...,s Health Initiative (WHI) Study published today i... The pooled analysis,showed no apparent increase i...rmone therapy close to menopause. , The publicatio...
Other Medicine Technology:Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 2New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 3New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 4New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 5New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 6
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: